Engineered Magnetic Resonance Nanoprobes for Visualizing Tumor Programmed Cell Death Ligand 1 Level and Enhancing...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Tumor programmed cell death ligand 1 (PD-L1) expression is a key target for cancer therapy and imaging.
• Current methods for visualizing PD-L1 expression and therapeutic targeting are limited.

Purpose of the Study:

• To develop a novel nanoplatform for simultaneous visualization of PD-L1 expression and synergistic cancer therapy.
• To evaluate the efficacy of the nanoplatform in magnetic resonance imaging (MRI) and combined radio-immunotherapy.

Main Methods:

• Construction of a gadolinium-hybridized platinum nanoplatform functionalized with PD-L1-antagonistic affibody (ZPD-L1), termed GPPZ.
• Utilizing GPPZ for targeted MRI visualization of PD-L1 expression in tumors.
• Assessing GPPZ's catalytic activities for radiotherapy sensitization and immunogenic cell death induction.
• Evaluating GPPZ's role in enhancing tumor immunotherapy by inhibiting PD-1/PD-L1 interactions.

Main Results:

• GPPZ demonstrated efficient PD-L1 targeting and enabled MRI visualization of PD-L1 expression in tumors.
• The nanoplatform catalyzed oxygen and hydroxyl radical production, sensitizing radiotherapy and enhancing immunogenic cell death.
• GPPZ effectively inhibited T cell immune suppression, boosting immunotherapy.
• Systemic delivery of GPPZ showed no significant side effects in histological and hematological examinations.

Conclusions:

• The developed GPPZ nanoplatform shows significant promise for enhanced MRI visualization of tumor PD-L1 levels.
• GPPZ offers a synergistic approach for combined radio-immunotherapy, improving cancer treatment strategies.